OBJECTIVE: To determine the utility of sequential MRI-estimated proton density fat fraction (MRI-PDFF) for quantification of the longitudinal changes in liver fat content in individuals with nonalcoholic fatty liver disease (NAFLD). METHODS: A total of 18 consecutive individuals (M/F: 10/8, mean age: 47.7±9.8 years) diagnosed with NAFLD, who underwent sequential PDFF calculations for the quantification of hepatic steatosis at two different time points, were included in the study. All patients underwent T1-independent volumetric multi-echo gradient-echo imaging with T2* correction and spectral fat modeling. RESULTS: A close correlation for quantification of hepatic steatosis between the initial MRI-PDFF and liver biopsy was observed (rs=0.758, p<0.001). The median interval between two sequential MRI-PDFF measurements was 184 days. From baseline to the end of the follow-up period, serum GGT level and homeostasis model assessment score were significantly improved (p=0.015, p=0.006, respectively), whereas BMI, serum AST, and ALT levels were slightly decreased. MRI-PDFFs were significantly improved (p=0.004). A good correlation between two sequential MRI-PDFF calculations was observed (rs=0.714, p=0.001). With linear regression analyses, only delta serum ALT levels had a significant effect on delta MRI-PDFF calculations (r2=38.6%, p=0.006). At least 5.9% improvement in MRI-PDFF is needed to achieve a normalized abnormal ALT level. The improvement of MRI-PDFF score was associated with the improvement of biochemical parameters in patients who had improvement in delta MRI-PDFF (p<0.05). CONCLUSIONS: MRI-PDFF can be used for the quantification of the longitudinal changes of hepatic steatosis. The changes in serum ALT levels significantly reflected changes in MRI-PDFF in patients with NAFLD.
OBJECTIVE: To determine the utility of sequential MRI-estimated proton density fat fraction (MRI-PDFF) for quantification of the longitudinal changes in liver fat content in individuals with nonalcoholic fatty liver disease (NAFLD). METHODS: A total of 18 consecutive individuals (M/F: 10/8, mean age: 47.7±9.8 years) diagnosed with NAFLD, who underwent sequential PDFF calculations for the quantification of hepatic steatosis at two different time points, were included in the study. All patients underwent T1-independent volumetric multi-echo gradient-echo imaging with T2* correction and spectral fat modeling. RESULTS: A close correlation for quantification of hepatic steatosis between the initial MRI-PDFF and liver biopsy was observed (rs=0.758, p<0.001). The median interval between two sequential MRI-PDFF measurements was 184 days. From baseline to the end of the follow-up period, serum GGT level and homeostasis model assessment score were significantly improved (p=0.015, p=0.006, respectively), whereas BMI, serum AST, and ALT levels were slightly decreased. MRI-PDFFs were significantly improved (p=0.004). A good correlation between two sequential MRI-PDFF calculations was observed (rs=0.714, p=0.001). With linear regression analyses, only delta serum ALT levels had a significant effect on delta MRI-PDFF calculations (r2=38.6%, p=0.006). At least 5.9% improvement in MRI-PDFF is needed to achieve a normalized abnormal ALT level. The improvement of MRI-PDFF score was associated with the improvement of biochemical parameters in patients who had improvement in delta MRI-PDFF (p<0.05). CONCLUSIONS: MRI-PDFF can be used for the quantification of the longitudinal changes of hepatic steatosis. The changes in serum ALT levels significantly reflected changes in MRI-PDFF in patients with NAFLD.
Authors: Zobair M Younossi; Rohit Loomba; Quentin M Anstee; Mary E Rinella; Elisabetta Bugianesi; Giulio Marchesini; Brent A Neuschwander-Tetri; Lawrence Serfaty; Francesco Negro; Stephen H Caldwell; Vlad Ratziu; Kathleen E Corey; Scott L Friedman; Manal F Abdelmalek; Stephen A Harrison; Arun J Sanyal; Joel E Lavine; Philippe Mathurin; Michael R Charlton; Zachary D Goodman; Naga P Chalasani; Kris V Kowdley; Jacob George; Keith Lindor Journal: Hepatology Date: 2018-07 Impact factor: 17.425
Authors: Elhamy R Heba; Ajinkya Desai; Kevin A Zand; Gavin Hamilton; Tanya Wolfson; Alexandra N Schlein; Anthony Gamst; Rohit Loomba; Claude B Sirlin; Michael S Middleton Journal: J Magn Reson Imaging Date: 2015-07-22 Impact factor: 4.813
Authors: Michael S Middleton; Mark L Van Natta; Elhamy R Heba; Adina Alazraki; Andrew T Trout; Prakash Masand; Elizabeth M Brunt; David E Kleiner; Edward Doo; James Tonascia; Joel E Lavine; Wei Shen; Gavin Hamilton; Jeffrey B Schwimmer; Claude B Sirlin Journal: Hepatology Date: 2018-01-26 Impact factor: 17.425
Authors: Francesco Paparo; Giovanni Cenderello; Matteo Revelli; Lorenzo Bacigalupo; Mariangela Rutigliani; Daniele Zefiro; Luca Cevasco; Maria Amico; Roberto Bandelloni; Giovanni Cassola; Gian Luca Forni; Gian Andrea Rollandi Journal: Biomed Res Int Date: 2015-03-19 Impact factor: 3.411
Authors: Tim G St Pierre; Michael J House; Sander J Bangma; Wenjie Pang; Andrew Bathgate; Eng K Gan; Oyekoya T Ayonrinde; Prithi S Bhathal; Andrew Clouston; John K Olynyk; Leon A Adams Journal: PLoS One Date: 2016-08-08 Impact factor: 3.240